Evidence map›Paper›PMID 34584219›Full record

ArticleOncogene2021

Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation.

M Guy Roukens, Cynthia L Frederiks, Danielle Seinstra, Luca Braccioli, Antoine A Khalil, Cornelieke Pals, Simon De Neck, Laura Bornes, Evelyne Beerling, Michal Mokry and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Organoids in breast cancer translational research: intersection of technologies.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

M Guy RoukensRegenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands. m.g.roukens-2@umcutrecht.nl.ORCID http://orcid.org/0000-0002-4270-8678
Cynthia L FrederiksRegenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands.
Danielle SeinstraDepartment of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, The Netherlands.
Luca BraccioliRegenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands.
Antoine A KhalilCenter for Molecular Medicine Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands.
Cornelieke PalsRegenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands.
Simon De NeckDepartment Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Laura BornesDepartment of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-9721-1223
Evelyne BeerlingDepartment of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, The Netherlands.
Michal MokryLaboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-5298-4852
Alain de BruinDepartment Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Bart WestendorpDepartment Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-1043-3638
Jacco van RheenenDepartment of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8175-1647
Paul J CofferRegenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands. pcoffer@umcutrecht.nl.ORCID http://orcid.org/0000-0001-8775-1939
Utrecht University · NLThe Netherlands Cancer Institute · NLUniversity Medical Center Groningen · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In breast cancer the transcription factor SOX4 has been shown to be associated with poor survival, increased tumor size and metastasis formation. This has mostly been attributed to the ability of SOX4 to regulate Epithelial-to-Mesenchymal-Transition (EMT). However, SOX4 regulates target gene transcription in a context-dependent manner that is determined by the cellular and epigenetic state. In this study we have investigated the loss of SOX4 in mammary tumor development utilizing organoids derived from a PyMT genetic mouse model of breast cancer. Using CRISPR/Cas9 to abrogate SOX4 expression, we found that SOX4 is required for inhibiting differentiation by regulating a subset of genes that are highly activated in fetal mammary stem cells (fMaSC). In this way, SOX4 re-activates an oncogenic transcriptional program that is regulated in many progenitor cell-types during embryonic development. SOX4-knockout organoids are characterized by the presence of more differentiated cells that exhibit luminal or basal gene expression patterns, but lower expression of cell cycle genes. In agreement, primary tumor growth and metastatic outgrowth in the lungs are impaired in SOX4

Indexed as

AnimalsBreast NeoplasmsCell Cycle ProteinsCRISPR-Cas SystemsEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticGene SilencingHumansLung NeoplasmsMiceNeoplasm TransplantationOrganoidsSOXC Transcription FactorsCell Cycle ProteinsSOX4 protein, humanSox4 protein, mouseSOXC Transcription Factors

Identifiers

PMID34584219
PMCPMC8585668
OpenAlexW3202960137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.